Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page
- Check2 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed, updating the page's version metadata without changes to the core study details.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check31 days agoChange DetectedVersion updated from v3.4.3 to v3.5.0 on the page, indicating a platform-level update without changes to study data or content.SummaryDifference0.1%

- Check38 days agoChange DetectedRevision: v3.4.3 was added, replacing the previous v3.4.2 in the revision history.SummaryDifference0.1%

- Check59 days agoChange DetectedResults section updated with data on dose-limiting toxicities, timing, and RECIST responses. Exploratory biomarker endpoints were removed.SummaryDifference3%

- Check66 days agoChange DetectedAdded Revision: v3.4.2 and removed Revision: v3.4.1 along with the funding/operating-status notice. There are no visible changes to the study details or results.SummaryDifference0.5%

- Check73 days agoChange DetectedAdministrative notices were added: a government funding lapse notice and an update to version 3.4.1. The prior version 3.4.0 was removed.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.